Loading
Latest filing published 04 Jun 2021 for Vallon Pharmaceuticals, Inc., €12k.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
This profile gathers the share dealings of Leanne M. Kelly across 2 companies, led by GRI BIO, Inc. and Genaera Corp. Between 11 December 2007 and 4 June 2021, the trades on record add up to 4 filings.
Every open-market trade on record is a purchase: 3 purchases worth €21k, and no sale. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 1 option exercise. 2021 to date brings 3 purchases and no sales.
The median purchase comes to €5,071. Of 3 purchases, 3 formed part of a group of insiders buying within 30 days of each other. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.
The newest entry dates from 4 June 2021: an open-market purchase of €3,622, in GRI BIO, Inc. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
1 of 1 declaration